sorafenib has been researched along with benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) | Trials (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) | Recent Studies (post-2010) (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,897 | 0 | 411 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buettner, R; Chang, S; Hedvat, M; Jove, R; Jove, V; Liu, L; Scuto, A; Tian, Y; Van Meter, T; Wen, W; Yang, F; Yen, Y; Yip, ML | 1 |
1 other study(ies) available for sorafenib and benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
| Article | Year |
|---|---|
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cerebellar Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Medulloblastoma; NF-kappa B; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Sorafenib; Tumor Cells, Cultured | 2012 |